Profile data is unavailable for this security.
About the company
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
- Revenue in USD (TTM)112.00k
- Net income in USD-15.75m
- Incorporated1990
- Employees21.00
- LocationAIM ImmunoTech Inc2117 SW Highway 484OCALA 34473-7949United StatesUSA
- Phone+1 (352) 448-7797
- Fax+1 (352) 480-4620
- Websitehttps://aimimmuno.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Propanc Biopharma Inc | 0.00 | -67.00m | 3.06m | 1.00 | -- | 0.2485 | -- | -- | -13.54 | -13.54 | 0.00 | 0.851 | 0.00 | -- | -- | 0.00 | -869.88 | -- | -1,782.95 | -- | -- | -- | -- | -- | -- | -74.43 | 0.0492 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Hcw Biologics Inc | 422.03k | -22.21m | 3.11m | 36.00 | -- | -- | -- | 7.37 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 3.27m | 5.00 | -- | 0.1484 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| Oragenics Inc | 0.00 | -10.90m | 3.50m | 3.00 | -- | 0.3526 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -8.99m | 3.55m | 3.00 | -- | -- | -- | -- | -0.1302 | -0.1302 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -129.27 | -96.94 | -145.04 | -116.42 | -- | -- | -- | -- | -- | -- | 34.30 | -- | -- | -- | 67.91 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 3.56m | 17.00 | -- | 0.3874 | -- | 1.06 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.62m | 21.00 | -- | -- | -- | 32.28 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.68m | 4.00 | -- | 0.2112 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -9.17m | 3.82m | 4.00 | -- | 0.7425 | -- | -- | -8.54 | -8.54 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -151.72 | -158.12 | -291.07 | -208.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.26 | -- | -- | -- |
| PMGC Holdings Inc | 285.95k | -4.48m | 3.87m | 2.00 | -- | 0.0261 | -- | 13.52 | -57.57 | -129.01 | 3.93 | 45.64 | 0.0219 | 0.373 | 1.98 | 142,975.00 | -34.29 | -- | -48.32 | -- | 27.29 | -- | -1,567.42 | -- | 1.77 | -32.16 | 0.2734 | -- | -- | -- | -142.45 | -- | -- | -- |
| Weed Inc | 0.00 | -755.25k | 3.87m | 2.00 | -- | -- | -- | -- | -0.0058 | -0.0058 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -133.78 | -117.17 | -- | -371.94 | -- | -- | -- | -- | -- | -22.55 | -- | -- | -- | -- | -1,518.25 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.89m | 3.00 | -- | 0.5554 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.02m | 3.00 | -- | 0.1753 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to AIM ImmunoTech Inc's reporting currency: US Dollar USD
3.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 69.62k | 2.57% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 17.52k | 0.65% |
| Geode Capital Management LLCas of 31 Dec 2025 | 17.39k | 0.64% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 865.00 | 0.03% |
| UBS Securities LLCas of 31 Dec 2025 | 379.00 | 0.01% |
| Community Bank NA (Private Banking New York)as of 31 Dec 2025 | 132.00 | 0.01% |
| Tower Research Capital LLCas of 31 Dec 2025 | 125.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 23.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2025 | 15.00 | 0.00% |
| Hoey Investments, Inc.as of 31 Dec 2025 | 10.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
